公开(公告)号：WO2008114011A2

公开(公告)日：2008-09-25

申请号：PCT/GB2008/000967

申请日：2008-03-19

Applicant: MEDIMMUNE LIMITED ,  GULER-GANE, Gulin ,  HOLGATE, Robert, George, Edward ,  JERMUTUS, Lutz, Ulrich, Jochen, Wilhelm ,  LEVENS, Jacqueline, Michaela ,  LUND, John, Norman ,  STEWART, Ross, Anthony ,  THOM, Albert, George ,  WEBSTER, Carl

Inventor： GULER-GANE, Gulin ,  HOLGATE, Robert, George, Edward ,  JERMUTUS, Lutz, Ulrich, Jochen, Wilhelm ,  LEVENS, Jacqueline, Michaela ,  LUND, John, Norman ,  STEWART, Ross, Anthony ,  THOM, Albert, George ,  WEBSTER, Carl

IPC: C07K16/00

CPC classification number: C07K16/00 ,  C07K16/2887 ,  C07K2317/72 ,  C07K2317/732 ,  C40B30/04 ,  C40B40/10 ,  C40B50/10

Abstract: The present invention relates to methods for selecting, obtaining or producing Fc variant polypeptides which show altered recognition for an Fc ligand (e.g., FcγR, CIq). Additionally, the Fc variant polypeptides may have altered antibody-dependent cell-mediated cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) activity. The invention further provides methods and protocols for the application of said Fc variant polypeptides particularly for therapeutic purposes.

Abstract translation: 本发明涉及用于选择，获得或产生对Fc配体（例如，FcγR，C1q）显示改变的识别的Fc变体多肽的方法。 另外，Fc变体多肽可能具有改变的抗体依赖性细胞介导的细胞毒性（ADCC）和/或补体依赖性细胞毒性（CDC）活性。 本发明还提供了用于应用所述Fc变体多肽的方法和方案，特别是用于治疗目的。

公开(公告)号：WO2008114011A3

公开(公告)日：2008-11-20

申请号：PCT/GB2008000967

申请日：2008-03-19

Applicant: MEDIMMUNE LTD ,  GULER-GANE GULIN ,  HOLGATE ROBERT GEORGE EDWARD ,  JERMUTUS LUTZ ULRICH JOCHEN WILHELM ,  LEVENS JACQUELINE MICHAELA ,  LUND JOHN NORMAN ,  STEWART ROSS ANTHONY ,  THOM ALBERT GEORGE ,  WEBSTER CARL

Inventor： GULER-GANE GULIN ,  HOLGATE ROBERT GEORGE EDWARD ,  JERMUTUS LUTZ ULRICH JOCHEN WILHELM ,  LEVENS JACQUELINE MICHAELA ,  LUND JOHN NORMAN ,  STEWART ROSS ANTHONY ,  THOM ALBERT GEORGE ,  WEBSTER CARL

IPC: C12N15/10 ,  A61K39/395 ,  A61P35/00 ,  C40B50/10

CPC classification number: C07K16/00 ,  C07K16/2887 ,  C07K2317/72 ,  C07K2317/732 ,  C40B30/04 ,  C40B40/10 ,  C40B50/10

Abstract: The present invention relates to methods for selecting, obtaining or producing Fc variant polypeptides which show altered recognition for an Fc ligand (e.g., Fc?R, CIq). Additionally, the Fc variant polypeptides may have altered antibody-dependent cell-mediated cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) activity. The invention further provides methods and protocols for the application of said Fc variant polypeptides particularly for therapeutic purposes.

Abstract translation: 本发明涉及用于选择，获得或产生对Fc配体（例如FcγR，C1q）显示改变的识别的Fc变体多肽的方法。 另外，Fc变体多肽可能具有改变的抗体依赖性细胞介导的细胞毒性（ADCC）和/或补体依赖性细胞毒性（CDC）活性。 本发明还提供了用于应用所述Fc变体多肽的方法和方案，特别是用于治疗目的。